TimesSquare Capital Management LLC Acquires 44,646 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

TimesSquare Capital Management LLC lifted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 39.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 158,868 shares of the company’s stock after acquiring an additional 44,646 shares during the quarter. TimesSquare Capital Management LLC owned approximately 0.55% of Krystal Biotech worth $24,888,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new position in Krystal Biotech during the 3rd quarter worth about $40,000. Values First Advisors Inc. acquired a new position in shares of Krystal Biotech in the 3rd quarter valued at about $53,000. Huntington National Bank lifted its stake in shares of Krystal Biotech by 97.6% in the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after purchasing an additional 283 shares during the period. Blue Trust Inc. lifted its stake in Krystal Biotech by 242.4% in the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after purchasing an additional 412 shares during the last quarter. Finally, KBC Group NV lifted its stake in Krystal Biotech by 25.9% in the third quarter. KBC Group NV now owns 642 shares of the company’s stock valued at $117,000 after purchasing an additional 132 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on KRYS. HC Wainwright restated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday. Citigroup upped their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Chardan Capital reissued a “buy” rating and issued a $212.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 18th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Krystal Biotech has a consensus rating of “Buy” and an average target price of $206.67.

Krystal Biotech Trading Up 12.4 %

Shares of NASDAQ:KRYS opened at $176.17 on Thursday. The stock’s 50-day moving average price is $157.40 and its 200-day moving average price is $175.17. The stock has a market capitalization of $5.07 billion, a P/E ratio of 99.53 and a beta of 0.84. Krystal Biotech, Inc. has a 12-month low of $107.50 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same period in the prior year, the business posted $0.30 earnings per share. Krystal Biotech’s revenue for the quarter was up 116.4% on a year-over-year basis. As a group, research analysts predict that Krystal Biotech, Inc. will post 3.22 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).